Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma (Q87132621)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 July 2013

Language	Label	Description	Also known as
English	Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma	scientific article published on 23 July 2013

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Takanori Teshima

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Toshihiro Miyamoto

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Goichi Yoshimoto

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Tomohiko Kamimura

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Tsuyoshi Muta

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Shuichiro Takashima

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Yoshikiyo Ito

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Motoaki Shiratsuchi

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Ilseung Choi

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Koji Kato

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Katsuto Takenaka

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Hiromi Iwasaki

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Yasushi Takamatsu

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Koichi Akashi

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

23 July 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

International Journal of Hematology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

98

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

337-345

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23877150%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

https://scigraph.springernature.com/pub.10.1007/s12185-013-1402-0

0 references

Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple Myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenalidomide after stem-cell transplantation for multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma: a feasibility study in Japanese population

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current approaches for the treatment of multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Investigation of the freely available easy-to-use software 'EZR' for medical statistics

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q87132621&oldid=1618676643"